SINTX TechnologiesSINT +3.78%27 EBITDA Margin % is -884.33% as of Mar. 2026. GuruFocus rates SINT with a GF Score™ of 27/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, SINTX Technologies ranks worse than 94.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SINTX Technologies's EBITDA for the
three
months ended in Mar. 2026 was $-2.65 Mil. SINTX Technologies's Revenue for the
three
months ended in Mar. 2026 was $0.30 Mil. Therefore, SINTX Technologies's EBITDA margin for the quarter that ended in Mar. 2026 was -884.33%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SINTX Technologies EBITDA Margin % Related Terms
SINTX Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SINTX Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SINT vs VVOS, AIDX, ALUR: EBITDA Margin % Comparison
For the Medical Devices subindustry, SINTX Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SINTX Technologies EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SINTX Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SINTX Technologies (SINT) has a EBITDA Margin % of -884.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SINTX Technologies and its competitors. According to the industry distribution chart, SINTX Technologies ranks #775 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 95%.
Is SINTX Technologies' EBITDA Margin % too high?
SINTX Technologies' current EBITDA Margin % is -884.33%. Based on the distribution chart, SINTX Technologies ranks #775 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SINTX Technologies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SINTX Technologies' EBITDA Margin % compare to VVOS and AIDX?
According to the Medical Devices & Instruments industry distribution chart, SINTX Technologies ranks #775 out of 816 companies for EBITDA Margin %. This places SINTX Technologies in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SINTX Technologies and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SINTX Technologies's current EBITDA Margin % is -884.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SINTX Technologies stock overvalued right now?
Based on GuruFocus' analysis, SINTX Technologies (SINT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.93 — trading 1186.7% above its estimated fair value. The current EBITDA Margin % is -884.33%. SINTX Technologies' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SINTX Technologies (SINT), the current EBITDA Margin % is -884.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SINTX Technologies (SINT) Overvalued in 2026?
Based on GuruFocus' analysis, SINTX Technologies stock appears to be overvalued.
The current stock price of $1.93 is trading 1186.7% above its estimated GF Value™ of $0.15.
GuruFocus considers SINTX Technologies to be Significantly Overvalued.
Key valuation signals for SINT:
EBITDA Margin %: -884.33%
GF Value™: $0.15 vs. price of $1.93 (1186.7% above fair value)
No single metric tells the full story. See the SINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
27GF Score
Get the complete analysis for SINT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SINT has been successfully added to your 
